Free Trial
NASDAQ:ITCI

Intra-Cellular Therapies (ITCI) Stock Price, News & Analysis

Intra-Cellular Therapies logo
$131.87 0.00 (0.00%)
As of 04/2/2025

About Intra-Cellular Therapies Stock (NASDAQ:ITCI)

Key Stats

Today's Range
$131.87
$131.87
50-Day Range
$131.87
$131.87
52-Week Range
$70.90
$131.98
Volume
N/A
Average Volume
1.54 million shs
Market Capitalization
$14.05 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$109.70
Consensus Rating
Hold

Company Overview

Intra-Cellular Therapies Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
13th Percentile Overall Score

ITCI MarketRank™: 

Intra-Cellular Therapies scored higher than 13% of companies evaluated by MarketBeat, and ranked 882nd out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Intra-Cellular Therapies has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on 2 buy ratings, 10 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Intra-Cellular Therapies has received no research coverage in the past 90 days.

  • Read more about Intra-Cellular Therapies' stock forecast and price target.
  • Earnings Growth

    Earnings for Intra-Cellular Therapies are expected to grow in the coming year, from ($0.64) to $0.19 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Intra-Cellular Therapies is -151.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Intra-Cellular Therapies is -151.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Intra-Cellular Therapies has a P/B Ratio of 21.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for ITCI.
  • Dividend Yield

    Intra-Cellular Therapies does not currently pay a dividend.

  • Dividend Growth

    Intra-Cellular Therapies does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for ITCI.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Intra-Cellular Therapies this week, compared to 6 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Intra-Cellular Therapies insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 2.60% of the stock of Intra-Cellular Therapies is held by insiders.

  • Percentage Held by Institutions

    92.33% of the stock of Intra-Cellular Therapies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Intra-Cellular Therapies' insider trading history.
Receive ITCI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intra-Cellular Therapies and its competitors with MarketBeat's FREE daily newsletter.

ITCI Stock News Headlines

This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.
Intra-Cellular Therapies
See More Headlines

ITCI Stock Analysis - Frequently Asked Questions

Intra-Cellular Therapies' stock was trading at $83.52 at the beginning of 2025. Since then, ITCI shares have increased by 57.9% and is now trading at $131.87.

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) issued its quarterly earnings data on Friday, February, 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.08) by $0.08. The biopharmaceutical company earned $199.22 million during the quarter, compared to analysts' expectations of $205.08 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative trailing twelve-month return on equity of 9.93%.

Shares of ITCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Intra-Cellular Therapies investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and Southern First Bancshares (SFST).

Company Calendar

Last Earnings
2/21/2025
Today
7/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ITCI
CIK
1567514
Employees
560
Year Founded
N/A

Price Target and Rating

High Price Target
$132.00
Low Price Target
$74.00
Potential Upside/Downside
-16.8%
Consensus Rating
Hold
Rating Score (0-4)
2.17
Research Coverage
12 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.73)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$139.67 million
Net Margins
-14.07%
Pretax Margin
-13.87%
Return on Equity
-9.93%
Return on Assets
-8.38%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.66
Quick Ratio
7.51

Sales & Book Value

Annual Sales
$680.50 million
Price / Sales
20.64
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$6.15 per share
Price / Book
21.44

Miscellaneous

Outstanding Shares
106,522,000
Free Float
103,563,000
Market Cap
$14.05 billion
Optionable
Optionable
Beta
0.69

Social Links

2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:ITCI) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners